Role of prophylactic hysterectomy in patients at high risk for hereditary cancers

Gynecologic Oncology

Volumn 102, Issue 3, 2006, Pages 475-479

  Villella, Jeannine A ^a   Parmar, Madhu ^a   Donohue, Kathleen ^b   Fahey, Cathy ^b   Piver, M Steven ^b   Rodabaugh, Kerry ^a  

^a Department of Gynecologic Oncology ^*  (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Familial ovarian cancer; Hysterectomy; Prophylactic oophorectomy

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FISHER EXACT TEST; GYNECOLOGIC CANCER; HIGH RISK POPULATION; HUMAN; HYSTERECTOMY; LAPAROSCOPY; MAJOR CLINICAL STUDY; MENORRHAGIA; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL SIGNIFICANCE; UTERUS MYOMA;

ADULT; AGED; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; REOPERATION; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748449238     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.006     Document Type: Article

References (32)

1. Schildkraut J.M., and Thompson W.D. Familial ovarian cancer: a population-based case-control study. Am. J. Epidemiol. 128 3 (1988) 456-466
2. Whittemore A.S. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol. Oncol. 55 3 Pt 2 (1994) S15-S19
3. Swisher E. Hereditary cancers in obstetrics and gynecology. Clin. Obstet. Gynecol. 44 3 (2001) 450-463
4. Piver M.S., Baker T.R., Jishi M.F., Sandecki A.M., Tsukada Y., Natarajan N., et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71 2 Suppl (1993) 582-588
5. Averette H.E., and Nguyen H.N. The role of prophylactic oophorectomy in cancer prevention. Gynecol. Oncol. 55 3 Pt 2 (1994) S38-S41
6. Trimble E.L. The NIH Consensus Conference on Ovarian Cancer: screening, treatment, and follow-up. Gynecol. Oncol. 55 3 Pt 2 (1994) S1-S3
7. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273 6 (1995) 491-497
8. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J. Clin. Oncol. 14 5 (1996) 1730-1736 [discussion 1737-1740]
9. Easton D.F., Ford D., and Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56 1 (1995) 265-271
10. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336 20 (1997) 1401-1408
11. Lu K.H., Garber J.E., Cramer D.W., Welch W.R., Niloff J., Schrag D., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 14 (2000) 2728-2732
12. Rebbeck T.R. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 86 11 Suppl. (1999) 2493-2501
13. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 18 (1998) 1371-1388
14. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
15. Berg J.W., and Lampe J.G. High-risk factors in gynecologic cancer. Cancer 48 2 Suppl. (1981) 429-441
16. Hanton E.M., Malkasian Jr. G.D., Dahlin D.C., and Pratt J.H. Primary carcinoma of the fallopian tube. Am. J. Obstet. Gynecol. 94 6 (1966) 832-839
17. Rose P.G., Shrigley R., and Wiesner G.L. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol. Oncol. 77 2 (2000) 319-320
18. Aziz S., Kuperstein G., Rosen B., Cole D., Nedelcu R., McLaughlin J., et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol. Oncol. 80 3 (2001) 341-345
19. Leeper K., Garcia R., Swisher E., Goff B., Greer B., and Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 1 (2002) 52-56
20. Agoff S.N., Mendelin J.E., Grieco V.S., and Garcia R.L. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am. J. Surg. Pathol. 26 2 (2002) 171-178
21. Podratz K.C., Podczaski E.S., Gaffey T.A., O'Brien P.C., Schray M.F., and Malkasian Jr. G.D. Primary carcinoma of the fallopian tube. Am. J. Obstet. Gynecol. 154 6 (1986) 1319-1326
22. Kneale B.L., and Attwood H.D. Primary carcinoma of the fallopian tube. Report of 13 cases. Am. J. Obstet. Gynecol. 94 6 (1966) 840-848
23. Semrad N., Watring W., Fu Y.S., Hallatt J., Ryoo M., and Lagasse L. Fallopian tube adenocarcinoma: common extraperitoneal recurrence. Gynecol. Oncol. 24 2 (1986) 230-235
24. Levine D.A., Lin O., Barakat R.R., Robson M.E., McDermott D., Cohen L., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80 3 (2001) 395-398
25. Hornreich G., Beller U., Lavie O., Renbaum P., Cohen Y., and Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol. Oncol. 75 2 (1999) 300-304
26. Pejovic T., Koul A., Olsen D., and Chambers J.T. No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report. Eur. J. Gynaecol. Oncol. 22 5 (2001) 336-338
27. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol. Oncol. 79 3 (2000) 477-481
28. Lavie O., Hornreich G., Ben-Arie A., Rennert G., Cohen Y., Keidar R., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol. Oncol. 92 2 (2004) 521-524
29. Paley P.J., Swisher E.M., Garcia R.L., Agoff S.N., Greer B.E., Peters K.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol. Oncol. 80 2 (2001) 176-180
30. Zweemer R.P., van Diest P.J., Verheijen R.H., Ryan A., Gille J.J., Sijmons R.H., et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol. Oncol. 76 1 (2000) 45-50
31. Hartley A., Rollason T., and Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin. Oncol. R Coll. Radiol. 12 1 (2000) 58-59
32. Colgan T.J., Murphy J., Cole D.E., Narod S., and Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25 10 (2001) 1283-1289